SOX1
Transcription factor SOX-1
Also known as: SOX1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O00570
- Gene
- SOX1
- Ensembl
- ENSG00000182968
- Chromosome
- 13
- Canonical length
- 391 aa
- Protein class
- Cancer-related genes, Predicted intracellular proteins, Transcription factors
OverviewNCBI Gene
This intronless gene encodes a member of the SOX (SRY-related HMG-box) family of transcription factors involved in the regulation of embryonic development and in the determination of the cell fate. The encoded protein may act as a transcriptional activator after forming a protein complex with other proteins. In mice, a similar protein regulates the gamma-crystallin genes and is essential for lens development. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
391 residues, UniProt reviewed canonical sequence.
>O00570|SOX1
1 MYSMMMETDL HSPGGAQAPT NLSGPAGAGG GGGGGGGGGG GGGAKANQDR VKRPMNAFMV
61 WSRGQRRKMA QENPKMHNSE ISKRLGAEWK VMSEAEKRPF IDEAKRLRAL HMKEHPDYKY
121 RPRRKTKTLL KKDKYSLAGG LLAAGAGGGG AAVAMGVGVG VGAAAVGQRL ESPGGAAGGG
181 YAHVNGWANG AYPGSVAAAA AAAAMMQEAQ LAYGQHPGAG GAHPHAHPAH PHPHHPHAHP
241 HNPQPMHRYD MGALQYSPIS NSQGYMSASP SGYGGLPYGA AAAAAAAAGG AHQNSAVAAA
301 AAAAAASSGA LGALGSLVKS EPSGSPPAPA HSRAPCPGDL REMISMYLPA GEGGDPAAAA
361 AAAAQSRLHS LPQHYQGAGA GVNGTVPLTH ILocalizationUniProt · AlphaFold · HPA
Whether an antibody against SOX1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.65
- Highest tissue expression
- 3.9 nTPM
Expression across tissuesHPA
Tissue
- hypothalamus: 3.9 nTPM
- amygdala: 2.8 nTPM
- basal ganglia: 2.7 nTPM
- cerebral cortex: 2.4 nTPM
- hippocampal formation: 1.7 nTPM
- midbrain: 1.5 nTPM
Single-cell type
- bergmann glia: 1.1 nCPM
- undifferentiated spermatogonia: 0.4 nCPM
- oligodendrocyte progenitor cells: 0.2 nCPM
- astrocytes: 0.1 nCPM
- brain inhibitory neurons: 0.1 nCPM
- differentiating spermatogonia: 0.1 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- hypothalamus: 32 nTPM
- midbrain: 10 nTPM
- basal ganglia: 8.5 nTPM
- cerebral cortex: 6.7 nTPM
- thalamus: 5.7 nTPM
- pons: 5.5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SOX1.
Disease | AutoantibodyPubMed
Conditions in which antibodies against SOX1 are reported. Each links to that disease's full target list.
- Lung Neoplasms 22
- Paraneoplastic Syndromes, Nervous System 6
- Encephalitis 3
- Hashimoto Disease 3
- Limbic Encephalitis 3
Showing 5 of 9 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for SOX1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
40 publications
- Autoantibodies in patients with fibromyalgia syndrome.
2025 · Pain · RCR 5.6 · 14 citations - SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.
2008 · Neurology · RCR 5 · 165 citations - Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome.
2020 · J Clin Neurol · RCR 2.4 · 38 citations - SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques.
2023 · J Neurol · RCR 1.8 · 13 citations - Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms.
2008 · Ann N Y Acad Sci · RCR 1.7 · 55 citations
Show 20 more of 40 total
- Caveats and Pitfalls of SOX1 Autoantibody Testing With a Commercial Line Blot Assay in Paraneoplastic Neurological Investigations.
2019 · Front Immunol · RCR 1.6 · 30 citations - SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes.
2012 · Acta Neurol Scand · RCR 1.4 · 37 citations - Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters.
2005 · Cancer · RCR 1.4 · 64 citations - Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications.
2023 · Neurology · RCR 1.2 · 8 citations - Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy.
2010 · J Neuroimmunol · RCR 1.2 · 38 citations - Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies.
2023 · Front Immunol · RCR 1.2 · 8 citations - Paraneoplastic Sensory Polyneuropathy Related to Anti-PD-L1-including Anticancer Treatment in a Patient with Lung Cancer.
2021 · Intern Med · RCR 1.1 · 14 citations - Paraneoplastic Opsoclonus-myoclonus Syndrome with Anti-Hu and Anti-SOX-1 Antibodies after Immune-checkpoint Inhibitor Treatment Combined with Chemotherapy in a Patient with Small-cell Lung Cancer.
2022 · Intern Med · RCR 1.1 · 12 citations - Coexistence of Anti-SOX1 and Anti-GABAB Receptor Antibodies with Autoimmune Encephalitis in Small Cell Lung Cancer: A Case Report.
2020 · Clin Interv Aging · RCR 0.9 · 12 citations - Paraneoplastic limbic encephalitis with SOX1 and PCA2 antibodies and relapsing neurological symptoms in an adolescent with Hodgkin lymphoma.
2017 · Eur J Paediatr Neurol · RCR 0.8 · 15 citations - Coexistence of anti-SOX1 and anti-GABAB receptor antibodies with paraneoplastic limbic encephalitis presenting with seizures and memory impairment in small cell lung cancer: A case report.
2022 · Front Immunol · RCR 0.8 · 9 citations - SOX-1 autoantibodies in patients with paraneoplastic neurological syndromes.
2009 · Autoimmun Rev · RCR 0.8 · 27 citations - Paraneoplastic Cerebellar Degeneration and Lambert-Eaton Myasthenic Syndrome with SOX-1 Antibodies.
2021 · Intern Med · RCR 0.6 · 7 citations - Anti-SOX1 Antibody-positive Small-cell Lung Cancer That Triggered Opsoclonus.
2023 · Intern Med · RCR 0.6 · 2 citations - Anti-SOX1 antibodies-positive paraneoplastic neurological syndromes caused by thyroid carcinoma: A case report.
2023 · Medicine (Baltimore) · RCR 0.6 · 4 citations - Anti-SOX1 antibody-positive paraneoplastic neurological syndrome presenting with Lambert-Eaton myasthenic syndrome and small cell lung cancer: A case report.
2020 · Thorac Cancer · RCR 0.6 · 10 citations - Coexistence of NMDAR, GAD65, and SOX1 antibody-associated autoimmune encephalitis.
2022 · Neurol Sci · RCR 0.4 · 4 citations - Paraneoplastic subacute sensory neuropathy with triple positive antineuronal antibodies associated with small-cell lung cancer.
2020 · BMJ Case Rep · RCR 0.4 · 6 citations - SOX-1 antibodies positive Lambert-Eaton myasthenic syndrome with occult small cell lung cancer: A case report.
2024 · Clin Respir J · RCR 0.4 · 2 citations - Expanding the spectrum of SOX1-antibodies in neuropathy: the coexistence of anti-SOX1 and Guillain-Barré syndrome-a case report.
2022 · Neurol Sci · RCR 0.4 · 3 citations
Reference: T cellIEDB
1 publication
- Identification and Validation of Th1-Selective Epitopes Derived from Proteins Overexpressed in Breast Cancer Stem Cells.
2025 · Vaccines (Basel) · 2 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.95
- gnomAD pLI
- 0.62
- gnomAD missense Z
- 0.58
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- brain development
- cellular response to leukemia inhibitory factor
- chromatin organization
- forebrain neuron development
- interneuron migration
- lens morphogenesis in camera-type eye
- negative regulation of transcription by RNA polymerase II
- neuron differentiation
- positive regulation of transcription by RNA polymerase II
- regulation of DNA-templated transcription
- regulation of oligodendrocyte differentiation
- ventral spinal cord interneuron specification
Molecular functions
- DNA binding
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity
- DNA-binding transcription factor activity, RNA polymerase II-specific
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SOX1 as an antibody target. Whether an autoantibody or antibody against SOX1 could matter depends on whether native SOX1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SOX1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SOX1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...